Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

House Set To Vote On Cures Nov. 30; Latest Version Includes 510(k)s In Breakthrough Pathway

Executive Summary

A combined House/Senate "21st Century Cures" package will get a vote in the House on Nov. 30, and soon in the Senate. The medical innovation package includes a breakthrough device pathway that, in its current form, would allow 510(k), as well as PMA and de novo, devices to participate. The bill also provides a modest $500m to help support a range of additional FDA device and drug pathway streamlining reforms. Meanwhile, it would authorize $4.8bn for the Precision Medicine Initiative, a BRAIN Initiative, and for cancer "Moonshot" research funds at NIH.

Advertisement

Related Content

Industry Urges FDA To Distinguish Between 510(k) Modification Factors
Innovation Bill Scorecard: Device, Diagnostic Provisions In Senate And House
Senate Moves To Floor Phase For Innovation Bill; Postmarket Surveillance, LDTs Could Get Attention
Senate Panel Passes Breakthrough Device, Other Measures; FDA Funding Debated
US Senate Committee Advances Device Review Reform Bills
Senate Bill Aimed At Streamlining Combo Product Regulation
Calls For More FDA Training In Lead Up To User-Fee Negotiations
'Cures' Bill Passes, As More Budget, Safety Debates Wait In The Wings
Fewer Device Submissions Sought In Subcommittee-Passed 'Cures' Bill
CDRH Launches Expedited Access Pathway, Extends To De Novos

Topics

Advertisement
UsernamePublicRestriction

Register

MT104139

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel